Index

Please note: “ACS” refers to the umbrella term “acute coronary syndromes”

ABCDE assessments, 39, 159-60
abximab, 58
abdominal aorta pulse, 28
ABG (arterial blood gases) monitoring, 117-18, 125
ablation, 148-9, 192
ACE (angiotensin-converting enzyme) inhibitors
  for heart failure, 183-4
  for NSTEMI, 69
  for secondary prevention, 220
  for STEMI, 81
  for unstable angina, 59
ACS see acute coronary syndromes (ACS)
action potential, 133-4
acute coronary syndromes (ACS), 1-5
categorisation, 47
clinical presentations (overview), 29, 37-8, 98-100
definitions and scope, 3-4, 36
identification and diagnosis, 98-100
diagnostic criteria, 37
history-taking, 99
investigation modalities, 40-9
biochemical markers, 43-6
ECG, 40-3
imaging, 48-9
risk stratification, 46-8
mortality data, 3
outcomes and service achievements, 2
pathologies (overview), 98
risk factors, 30
socio-economic burden, 2-3
therapeutic interventions (overview), 97-110
  non-pharmacological, 100-101
  oxygen therapy, 102
  pharmacological, 101-2
see also individual conditions
acute heart failure, 161-4
treatment, 164
adenosine, 148
adrenalin, 120
AF (atrial fibrillation), 121, 138, 143-4, 190-94
  ECG characteristics, 144, 191
treatments and management, 192-4
air transport, 243
airways management (cardiac arrest), 120, 159
aldosterone, 185
ALERT course (Portsmouth University), 157
alteplase (tPA), 107
ambulance transport, 243
ambulation regimes, 118
amiodarone, 120, 121, 148, 192
analgesia, 101-2
  for unstable angina, 57
  postoperative, 126
angina (refractory), 188-90
  see also angina (unstable)
angina (stable), 53
angina (unstable), 52-60
  assessment, 54-5
  characteristics, 53-4
  clinical presentation, 54
  investigations, 55-6
  pathogenesis, 53
risk assessment, 47-9
treatment strategies, 56-9
  analgesia and rest, 57
  anti-ischaemic therapies, 57
  anti-platelet therapies, 57-8
  anticoagulant therapies, 58-9
  plaque stabilisation, 59
  revascularisation, 59, 103
angiography, 33, 48-9, 103
  computed tomographic (CT), 49
Angiomax (bivalirudin), 59
angiotensin-converting enzyme (ACE) inhibitors
for heart failure, 183–4
for NSTEMI, 69
for secondary prevention, 220
for STEMI, 81
for unstable angina, 59
angiotensin-receptor blockers, 184, 185
anterior STEMI, 82–4
anti-arrhythmic drugs, 148
anti-ischaemic therapies
for NSTEMI, 69–70
for unstable angina, 57
anti-platelet therapies
for NSTEMI, 68–9
for unstable angina, 57–8
antibiotics, 127
anticoagulant therapies, 58–9
antidepressants, 214
antimicrobial therapy, 127
anxiety feelings, 212
aortic aneurysm, clinical signs, 28, 29
aortic dissection (acute), 22, 29
aortic valve closure, 25
apex beat, 24
apical impulse, 24
arcus, 21
Arixtra (fondaparinux), 58–9
arrhythmias, 38–9, 132–54
definitions and causes, 132–9
re-entry phenomena, 135
diagnosis and ECG analysis, 135–9
peri-arrest patients, 149
treatments, 147–9
ablation, 148–9
defibrillation, 147
drug therapies, 148
pacemakers, 148
vagal manoeuvres, 147
types, 139–47
atrial fibrillation (AF), 121, 138, 143–4
atrial flutter, 144–5
atrioventricular (AV) blocks, 140–43
bradyarrhythmias, 139
during surgery, 119–21
life-threatening, 146–7
Arrhythmias and Sudden Cardiac Death
( NSF for Coronary Heart Disease) (DH 2005b), 2
arterial blood gases (ABG) monitoring, 117–18, 125
arterial pulses, 21–2
aspirin
mode of action, 58
for NSTEMI, 68–9
for secondary prevention, 220
for STEMI, 80
for unstable angina, 57–8
ASSENT-4 trial, 109–10
assessment of the cardiovascular system, 19–34
general examination, 20–21
blood pressure measurement, 22
peripheral arteries and veins examination, 26–8
precordium examination, 236
auscultation, 25–6
inspection, 23–4
palpation, 24
pulse measures
abdominal aorta, 28
arterial, 21–2
carotid, 23
jugular venous pressure, 22–3
peripheral, 26–8
see also electrocardiography (ECG)
avulsion, 118–20
clinical examinations, 39
history-taking, 39–40, 98–9
investigations, 40–9
see also risk assessment
asystole, 119–21, 151–2
atenolol, 148
atherosclerotic plaques, 53
rupture, 53, 63–4, 74
atrial fibrillation (AF), 121, 138, 143–4, 190–94
ECG characteristics, 144, 191
treatments and management, 192–4
atrial flutter, 144–5
ECG characteristics, 42, 138, 144
atrioventricular (AV) blocks, 140–3
first degree, 140
second degree, 140–42
third degree, 142–3
atropine administration, 120
auscultation, 25–6
autonomic nervous system responses, 75–6
AV (atrioventricular) blocks, 140–3
first degree, 140
second degree, 140–42
third degree, 142–3
AVPU, 30
b-type natriuretic peptide (BNP), 182
Bair Huggers, 123
BCPR (bystander cardiopulmonary resuscitation), 13–14
beating heart surgery, 115–16
beta-blockers
  for arrhythmias, 148
  for heart failure, 185
  for NSTEMI, 69
  for secondary prevention, 220-21
  for STEMI, 81
  for unstable angina, 57
Bezold-Jarisch reflex, 38
biochemical markers, 32, 43-6
  for angina, 55-6
  for NSTEMI, 67-8
  for STEMI, 79
bioethics, 227-8
bivalirudin (Angiomax), 59
blood gases monitoring, 117-18, 125
blood pressure
  and diet, 210
  measurement, 22
blood tests, pre-surgery, 114
blood transfusions, postoperative, 124-5
BMI (body mass index), as risk indicator, 9
body surface area (BSA) measures, 114
brachial pulse, 26
bradyarrhythmias, 121, 139
bradycardia
  and peri-arrest, 149
  severe, 119-21
breathing, assessment, 30, 159
breathing techniques, post-surgery, 118
breathlessness, 38, 54, 64, 75
Bruce protocol, 33
bruits, 28
BSA (body surface area) measures, 114
bundle branch block, 42, 45
bystander cardiopulmonary resuscitation (BCPR), 13-14
c-reactive protein, 53, 56
cABG (coronary artery bypass grafts), 112-28
  management of complications, 119-23
  operation procedures, 115-16, 119-21
  patient preparation, 113-15, 119
  postoperative care, 116-23, 121-3
calcium channel blockers
  for arrhythmias, 148
  for NSTEMI, 69
  for unstable angina, 57
“call to balloon” (CTB) time measures, 105
candesartan, 185
capillary refill time (CRT), 21
cardiac ablation, 148-9, 192
cardiac action potential, 133-4
cardiac arrest, 38, 149-54
  during surgery, 119-21
  ECG characteristics, 150, 152
  non-shockable rhythms, 151-2
  reversible causes, 152, 153
  shockable rhythms, 150-51
  cardiac enzyme markers, 32, 43-6
    for angina, 55-6
    for NSTEMI, 67-8
    for STEMI, 79
  cardiac muscle, 133-4
  cardiac rate control therapies, 14-15, 150-51, 192, 187-8
    indications for use, 194
    see also defibrillation; pacemakers
  cardiac rehabilitation, 198-203, 214
    circuit classes, 245-7
  cardiac resynchronisation therapy (CRT), 187-8
  cardiac rhythm, 40-43, 192
    diagnostic investigations, 137-9
    indications for control, 194
    see also cardiac resynchronisation therapy (CRT); defibrillation; pacemakers
  cardiac tamponade, 119, 167-70
  cardiac troponin, 32, 46, 67, 79
  cardiogenic shock, 89-90
  cardioplegia, 115
  cardiopulmonary resuscitation (CPR), 120, 150-51, 153
    and DNAR orders, 231-2
    during surgery, 120
    early interventions, 13-14
  cardiovascular disease
    disease continuum, 4
    mortality trends, 3
    patient assessment and examination, 19-34
    risk factors, 9-10
  cardiovascular system, 19-34
    blood pressure measurement, 22
    general examination, 20-21
    peripheral arteries and veins examination, 26-8
    precordium examination, 236
      auscultation, 25-6
      inspection, 23-4
      palpation, 24
    pulse measures
      abdominal aorta, 28
      arterial, 21-2
      carotid, 23
      jugular venous pressure, 22-3
      peripheral, 26-8
      see also electrocardiography (ECG)
  cardioversion, 192
  cardioverter defibrillators, 187-8
  carotid pulse, 23
catecholamine cascade, 119
catheterisation, postoperative, 125
Chain of Survival (CPR) model, 13–14
chest, general examination, 23–6
chest compressions, 150
chest pain, 37–8
  causes, 30, 54, 64–5, 75, 77
  differential diagnosis, 29
  gender and ethnicity presentations, 91–3
PQRST assessment, 77
chest pain assessments, 28–31
  clinical examination, 30
  electrocardiography, 31
  history-taking, 28–30
  investigations, 32–3
  laboratory tests, 31–2
  rapid access clinics (RACPC’s), 7, 10–12
chest wall pain, 29
chest X-ray, 32
cholesterol, and diet, 210–11
chronic heart conditions see long-term cardiac conditions
circuit classes (rehabilitation), 245–7
CK-MB isoforms, 46, 67
clinical history-taking, 98–9
clopidogrel (Plavix)
  contraindications, 58
  dose, 58
  mode of action, 58
  for NSTEMI, 68–9
  for STEMI, 80
  for unstable angina, 57–8
  cognitive behavioural therapy (CBT), 213–14
collapse, 38
  Commissioning Guide for Services for Young People and Grown Ups with CHD (DH 2006), 2
community-based emergency interventions
defibrillation, 14–15
  first responder schemes, 15–16
computed tomographic (CT) angiography, 49
consent, 113, 230–31
cornea, 21
coronary angiography, 33, 48–9
coronary artery bypass grafts (CABG), 112–28
  management of complications, 119–23
  operation procedures, 115–16, 119–21
  patient preparation, 113–15, 119
  postoperative care, 116–23, 121–3
coronary artery spasm, 119–21
coronary heart disease (CHD)
  mortality rates, 1–2, 3
  risk factors, 9–10, 30
see also chest pain assessments
The Coronary Heart Disease NSF, progress report for 2008 (DH 2009a), 2
costochondritis, 29
CPR (cardiopulmonary resuscitation), 120, 150–51, 153
  and DNAR orders, 231–2
  during surgery, 120
  early interventions, 13–14
creatine kinase (CK) isoforms, 32, 45–6, 67
critical care outreach team (CCOT), 158
critical patients, transfer arrangements, 237–43
CRT see capillary refill time (CRT);
cardiac resynchronisation therapy (CRT)
CT angiography, 49
CTB (call to balloon) time measure, 105
cyanosis, signs and symptoms, 20–21
cyclizine, 80
Darzi, Lord, 1
depolarisation, 133–4
heartbeats, 134–5
depression, 93, 186–7, 212–14
diabetes
  and diet, 211
  and STEMI, 91
diamorphine use, 80
diaphoresis, 38, 65, 75–6
diet and nutrition advice, 186, 207–11
  cholesterol changes, 210–11
  diabetes, 211
  fat intake, 210
  Mediterranean diet, 207–9
omega-3 fatty acids, 210
weight management, 211
dietary fats, 210
digoxin, ECG characteristics, 43
diltiazem, 57
discharge arrangements, 128
disease registers, 8
diuretic therapies, 184–5
DNAR orders, 231–2
dobutamine, 87
dopamine, 87
Doppler echocardiography, 183
drains management, 125
drug therapies
early intervention principles, 101
facilitated PCI, 109–10
secondary prevention, 219–21
see also individual agents
dyssynchrony, 188
early ambulation regimes, 118
early warning score (EWS), 157–9
ECG investigations see
electrocardiography (ECG)
echocardiography, 32, 49, 183, 193
pre-surgery, 115
ECHOs see echocardiography
electrocardiography (ECG), 31, 40–3, 44–5
general characteristics and
irregularities, 40–41, 42–3, 44–5
of arrhythmias, 135–9
of atrial fibrillation, 144, 191
of cardiac arrest, 149–52
of heart block, 149
of heart failure (chronic), 182
of hyperkalaemia, 172
of myocardial demise, 76
of NSTEMI, 65–7
of STEMI, 78, 83–5
of tachyarrhythmias, 143–5
of torsades de pointes, 147
of unstable angina, 55–6
of ventricular tachycardia, 146
surgery-associated continuous
monitoring, 100–101, 118–19
electrolyte disorders, 170–6
electrophysiological responses (heart),
133–4, 135
emergency cardiac care, 156–76
access, 12–13
alert devices and risk tools, 157–9
community first responder schemes,
15–16
early outreach care teams, 157
precipitating conditions, 161–76
resuscitation guidelines, 120, 153
employment advice, 219
enalapril, 59
end-of-life issues, 231–3
epidemiological data gathering, 8
for risk assessment, 8–10
epigastric discomfort, 54
see also oesophagogastric disorders
eptifibatide, mode of action, 58
ethical grid, 229–30
ethical issues, 226–35
decision-making frameworks,
228–30
DNAR orders, 231–2
informed consent, 230–31
patient’s rights and responsibilities,
233–4
theory and principles, 226–8
withdrawal of active treatment,
232–3
ethnic minority groups, and STEMI,
91–2
EuroSCORE, 113–14
exercise prescription, 214–18
home-based programs, 216–18
risk assessments, 217–18
exercise tolerance testing, 33
eye examinations, 21
facial pallor, 20–21
facilitated percutaneous coronary
intervention, 109–10
fast tracking, 127
fat intake, 210
fatal arrhythmias, 119–21
femoral pulse, 27
fingernail clubbing, 21
“first responders”, 15–16
“Fitter Britain” campaign, 12
flat line (asystole), 119–21, 151–2
flecainide, 148
fluid balance, postoperative, 124–5
fluid intake, and heart failure, 185
foam cells, 53
fondaparinux (Arixtra), 58–9
foot pulses, 28
four quadrants approach, 228–9
Framingham risk scoring system, 8
gender and ACS, 92–3
General Practitioner Extraction Service
(UK), 9
glyceryl trinitrate (GTN), 57
glycoprotein IIb/IIIa inhibitors, 69, 70
GMS (general medical services)
contract, 8
government policy directions see Department of Health policy directions
GRACE registry, 47-8
Health and Social Care Standards and Planning Framework (2005/6; 2006/7), 7-8
healthy eating see diet and nutrition
heart block
atrioventricular (AV), 140-43
ECG characteristics, 42
treatments, 147-9
heart electrophysiology, 133-4
conduction system, 134-5
heart failure
acute, 161-4
chronic, 179-88
compensation mechanisms, 183
diagnosis and investigations, 180-83
lifestyle changes, 185-7
pharmacotherapy, 183-5
surgery and device therapy, 187-8
heart murmurs, 26
grades, 27
timing, 27
heart rate
bradycardias, 41
normal, 41
tachycardias, 41
heart sounds, 25-6, 27
heartbeats, 134-5
heartburn see oesophagogastric disorders
heparin
for NSTEMI, 69
for unstable angina, 58-9
mode of action, 58
post-surgery, 118
High Quality Care For All (DH 2008a), 1
history-taking for ACS, 39-40, 98-9
HMG-CoA reductase inhibitors (statins), 221
efficacy and outcomes, 6
mode of action, 59
hospital admissions
data projections, 3
length of stay and fast tracking, 127
see also postoperative care; surgery
hospital discharges, 128
“hyperglycaemic waist”, 10
hyperkalaemia, 171-3
hypermagnesaemia, 175-6
hypertension, post-surgery, 123
hypokalaemia, 173-4
hypermagnesaemia, 174-5
hypotension
blood pressure measures, 22
pre-surgery, 119
hypothermia, during surgery, 116
hyponatraemia, 22-3
pre-surgery, 119
identification of patients at risk see risk assessment
implantable cardioverter defibrillators, 187-8
inferior STEMI, 83, 87-8
informed consent, 113, 230-31
inotropes, 87
insulin resistance syndrome, 10
INTERHEART study, 8-9, 10
interventions for ACS see therapeutic interventions for ACS; under individual conditions
jugular venous pressure (JVP), 22-3
kyphoscoliosis, 23
left bundle branch block, 43, 45
left ventricular failure (LVF) post STEMI, 84-7
PA catheterisation, 90-91
“life checks” campaigns, 12
life support see cardiopulmonary resuscitation (CPR)
lifestyle advice, 7-8, 185-7, 206-11
diet and nutrition, 207-11
exercise, 214-18
key targets, 207
smoking cessation, 7, 206-7
lignocaine, 148
long-term cardiac conditions, 178-95
heart failure, 179-88
loop diuretics, 184-5
low output syndrome, 121
magnesium regulation, 174-6
hypermagnesaemia, 175-6
hypomagnesaemia, 174-5
markers see biochemical markers
Mediterranean diet, 207-9
metabolic acidosis, 118
metabolic alkalosis, 118
metoclopramide, 80
MEWS (modified early warning system), 158-9
mexililnine, 148
microatelectasis, 117-18
microvascular ischaemia, 93
mitral stenosis, 24
auscultation, 25-6
Index

Mobitz type-1 block, 140–41
Mobitz type-2 block, 141–2
monitoring and rest regimes, 100–101
morphine use, 80, 101–2
mortality rates for CHD, 2–3, 6
Mosteller formula, 114
MPS see myocardial perfusion scintigraphy (MPS)
myocardial perfusion scintigraphy (MPS), 33
myocardial trauma, 74–5, 76
myocytes, 133–4
myoglobin, 67
NASPE/BPEG codes, 249–50
National Infarct Angioplasty Project (NIAP) (DH 2008b), 2
National Quality Boards, 1
National Service Framework for Coronary Heart Disease (DH 2009a), 1
nausea, 38
neck pain, 54
neurological assessment, post-surgery, 124
neurological complications (post-surgery), 124
New York Heart Association (CCNTHA) classifications, 181
nitrates, 57, 69
nitroglycerine, 119–21
non-ST segment elevation myocardial infarction (NSTEMI), 62–71
characteristics, 64–6
biochemical markers, 67–8
ECG profiles, 42–3, 45, 65–6
definitions, 63
diagnosis, 66–8
pathogenesis, 63–4
risk assessment, 47–9
risk factors, 70
secondary prevention regimes, 69
treatment strategies, 68–70, 102–3
analgesia, 68
anti-ischaemic therapies, 69–70
anti-platelet agents, 68–9
anti-thrombin agents, 69
revascularisation and angiography, 103
noradrenaline infusions, 123
NSTEMI see non-ST segment elevation myocardial infarction (NSTEMI)
numbness, 38
nurse roles
atrial fibrillation clinics, 192–4
postoperative care, 116–23
pre-admission clinics, 114–15
Rapid Access Chest Pain Clinics, 7, 10–12
nutrition see diet and nutrition advice
oedema, lower limbs, 21
oesophagogastric disorders, clinical presentations, 29
off-pump surgery, 115–16
“OLDCART” mnemonic (history-taking), 98–9
omega-3 fatty acids, 210
OPCAB (off-pump coronary artery bypass), 115–16
operation procedures, 115–16
see also surgery
opiates, 80, 101–2, 126
Our Health, Our Care, Our Say (Secretary of State for Health 2006), 12
outreach care teams, 157
oxygen therapy, 102
for STEMI, 80
P wave characteristics, 40–41, 42, 136
ECG analysis, 138
P–R interval irregularities, 30, 138
PA catheterisation, 90–91
PAC see pulmonary artery catheter (PAC)
pacemakers, 148, 248–50
cardiac resynchronisation therapy, 187–8
NASPE/BPEG codes, 249–50
pain (ischaemic), 53
pain control, 101–2
postoperative, 126
palpation, 24
palpitations, 54, 65
parasympathetic responses, 76–7
patient consent, 113, 230–31
patient transfers (theatre-to-specialist centres), 237–43
patient's rights and responsibilities, 233–4
PCD (post-cardiotomy delirium), 126
PEA (pulseless electrical activity), 151
pectus excavatum, 23
PEEP (positive end expiratory pressure), 115
percutaneous coronary intervention (PCI)
facilitated, 109–10
primary, 103–6
peri-arrest arrhythmias, 149
pericardial friction rub, 26
pericarditis, 164–7
  clinical presentations and ECG, 29, 166–7
  treatments, 167
peripheral pulses, 26–8
PiCCO, 123
plaque rupture, 53, 63–4, 74
plaque stabilisation therapies, 59
platelet activation pathways, 58
Plavix (clopidogrel)
  contraindications, 58
  dose, 58
  mode of action, 58
  for NSTEMI, 68–9
  for STEMI, 80
  for unstable angina, 57–8
pleurisy, clinical presentations, 29
PMI (point of maximal impulse), 24
point of care testing, 124–5
point of maximal impulse (PMI), 24
popliteal pulse, 27
post-cardiotomy delirium (PCD), 126
posterior STEMI, 83, 89
postoperative care, 116–23
  drains management, 125
  early ambulation, 118
  ECG monitoring, 118–19
  fluid balance, 124–5
  length of stay and fast tracking, 127
  management of complications, 121–3
  management of discharge arrangements, 128
  neurological care, 124
  nursing roles, 128
  pain management, 126
  post-24 hours, 123–4
  psychological factors, 126
  skin integrity, 126
  ventilation, 117–18
postoperative complications, 121–3
potassium channel blockers, 148
potassium regulation, 171–4
  hyperkalaemia, 171–3
  hypokalaemia, 173–4
pPCI (primary percutaneous coronary intervention), 103–6
PQRST chest pain assessment, 77
PR interval, 136
pre-admission clinics, 114–15
prevalence studies, for coronary heart disease, 3
prevention strategies for CVD, settings and modalities, 4
primary care delivery
  performance-related contracts, 8
  policy initiatives (overview), 7–8
primary percutaneous coronary intervention (pPCI), 103–6
primary prevention strategies, 4
  impact on mortality rates, 6
prostacyclin, 58
psychological factors in ACS, 93, 186–7, 211–13
psychosocial treatments for ACS, 7–8, 185–7, 206–11, 213–14
diet and nutrition, 207–11
exercise, 214–18
key targets, 207
smoking cessation, 7, 206–7
pulmonary artery catheter (PAC), 123
pulse
  abdominal aorta, 28
  absent, 151–2
  arterial, 21–2
  carotid, 23
  jugular venous pressure (JVP), 22–3
  peripheral, 26–8
  popliteal, 27
  radial, 21–2
pulseless electrical activity (PEA), 151
Q wave characteristics, 40–41
  irregularities, 42–3
QRISK algorithm, 9
QRS complex, 40–41, 136
  duration, 42, 137
QRS rate, 41
  assessment, 138
  irregularities, 42
QT interval, 137
Quality and Outcomes Frameworks (QoF), 8
R wave characteristics, 40–41
  irregularities, 42–3
R–R interval irregularities, 30
RAAS (renin-aldosterone-angiotensin system), 183
radial pulses, 21–2
ramipril, 59
Rapid Access Chest Pain Clinics (RACPCs), 7, 10–12
rapid diagnostic clinics, 7, 10–12
re-entry phenomena, 135
refractory period, 134
rehabilitation provisions, 198–203, 214
  circuit classes, 245–7
renin-aldosterone-angiotensin system (RAAS), 183
respiratory acidosis, 118
respiratory alkalosis, 118
respiratory rate, normal, 22
rest and monitoring regimes, 100–101
resuscitation see cardiopulmonary resuscitation (CPR)
resynchronisation therapy, 187–8
reteplase (RPA), 107
revascularisation
for angina, 59
for NSTEMI, 103
right bundle branch block, 43
right ventricular STEMI, 88
rights and responsibilities, 233–4
risk assessment
identification tools, 8–10, 47–8, 157–9
pre-surgery, 113–14
track and trigger systems, 158–9
risk factors, for cardiac disease, 9–10, 30
S wave characteristics, 40–41
salt intake, 185
saturated fats, 210
Saving Lives: Our Healthier Nation (DH 1999), 2, 7
SBAR approaches, 157
school fruit programme, 7
secondary prevention measures
(community-based), 4, 205–22
lifestyle changes, 206–11
pharmacotherapies, 219–21
psychological wellbeing, 211–18
psychosocial wellbeing, 218–19
sedatives, 124
sexual relationships, 218–19
shoulder pain, 54
sick sinus syndrome, 146
sinus bradycardia, 139
sinus rhythm irregularities (overview), 30
sinus tachycardia, 143
skin changes, 38
skin integrity, 126
smoking cessation, 7, 206–7
impact on mortality rates, 6
sodium channel blockers, 148
spirometry, 182
ST segment, 136–7
ST segment elevation myocardial infarction (STEMI), 73–94
assessment and diagnosis, 78–9
ECG characteristics, 42–3, 44
PA catheterisation, 91–2
clinical features, 75–7
and diabetes, 91
and ethnicity, 91–2
and gender, 92–3
mortality rates, 73
pathogenesis, 74–5
post-trauma complications, 81–2
cardiogenic shock, 89–90
depression, 93
PA catheterisation, 90–91
post-trauma continuing care, 93
region-specific trauma care, 93
region-specific trauma outcomes, 82–91
anterior infarcts, 82–4
inferior infarcts, 87–8
left ventricular failure (LVF), 84–7
posterior STEMI, 89
right ventricular STEMI, 88
rehabilitation, 93
risk assessment, 47–9
secondary prevention, 93
specific patient groups, 91–3
supportive nursing regimes, 82
treatment strategies, 79–81
facilitated percutaneous coronary intervention, 109–10
primary percutaneous coronary intervention (pPCI), 103–6
thrombolysis, 106–9
Starling’s law, 90
statins, 221
effect on plaques, 59
efficacy and outcomes, 6
STEMI see ST segment elevation myocardial infarction (STEMI)
sternum, 23
streptokinase, 107
stress tests see exercise tolerance testing
sudden cardiac death, 12–16
supraventricular tachycardia (SVT), 145
surgery
common types, 112
operation complications, 119–21
operation procedures, 115–16
patient consent, 113
patient preparation, 113–15
pre-admission clinics, 114–15
postoperative care, 116–23
SVR (systemic vascular resistance), 123
SVT (supraventricular tachycardia), 145
sweating, 38, 65, 75–6
syncope, 54
systemic vascular resistance (SVR), 123
T wave characteristics, 40–41, 137
irregularities, 42–3, 65
tachyarrhythmias, 121, 143–6
atrial fibrillation, 143–4
atrial flutter, 144–5
sinus tachycardia, 143
supraventricular tachycardia, 145
torsades de pointes, 146–7
ventricular, 146
tachycardias, in peri-arrest patients, 149
tamponade, 119, 167–70
TAVI (transcatheter aortic valve implantation), 116
tenecteplase (TNK), 107, 109–10
tertiary prevention strategies, 4
therapeutic interventions for ACS, 97–110
non-pharmacological, 100–101
pharmacological, 101–2
use of oxygen therapies, 102
thiazide diuretics, 185
thromboelastographs (TEG), 124–5
thrombolysis, 106–9
administration, 106–8
contraindications, 108
drawbacks, 109
drug agents, 107
effectiveness, 109
thrombolytic agents, 107
thromboxane α2, 58
thrombus, composition, 57–8
thyroid disease, signs and symptoms, 21
TIMI risk score, 48, 68
tirofiban, 58
torsades de pointes, 146–7
track and trigger systems, 158–9
training, emergency care, 157
transcatheter aortic valve implantation (TAVI), 116
transfers (theatre-to-specialist centres), 237–43
travel restrictions, 219
treatment modalities for ACS see therapeutic interventions for ACS; under individual conditions
treatment withdrawal, 232–3
troponin, 32–3, 46, 67, 79
sample intervals, 46
12-lead ECG investigations see electrocardiography (ECG)
UK General Practitioner Extraction Service, 9
utilitarianism, 227
vagal manoeuvres, 147
Valsalva manoeuvre, 147
vasoplegia, 121–3
ventilation
in cardiac arrest, 120
post-surgery, 117–18
ventricular fibrillation (VF), 119–21, 150
ventricular rate, 138
ventricular tachycardia (VT), 146, 149–50
verapamil, 57, 148
VF (ventricular fibrillation), 119–21, 150
vital signs examinations, 39
post-surgery, 118
voluntary service initiatives, community first responders, 15–16
vomiting, 38
VT (ventricular tachycardia), 146, 150–1
waist circumference measures, 9–10
warfarin, 123
weight management, 211
Wenkebach phenomenon, 140–41
withdrawal of treatment, 232–3
Wolff-Parkinson-White syndrome, 148
women, and coronary heart disease, 92–3
xanthelasma, 21